<p>Choriogonadotropin alfa injection is indicated for the induction of final follicular maturation and early luteinization in&nbsp;infertile&nbsp;women who have undergone pituitary&nbsp;desensitization and who have been appropriately pretreated with follicle stimulating hormones as part of an Assisted Reproductive Technology (ART) program such as&nbsp;in vitro&nbsp;fertilization&nbsp;and embryo transfer. Choriogonadotropin alfa PreFilled Syringe is also indicated for the induction of&nbsp;ovulation&nbsp;(OI) and pregnancy in anovulatory infertile patients in whom the cause of&nbsp;infertility&nbsp;is functional and not due to primary&nbsp;ovarian&nbsp;failure.<br />
<br />
Selection Of Patients:</p>

<ul>
	<li>Before treatment with gonadotropins is instituted, a thorough gynecologic and endocrinologic evaluation must be performed. This should include an assessment of&nbsp;pelvic&nbsp;anatomy. Patients with tubal obstruction should receive Choriogonadotropin Alfa PreFilled Syringe only if enrolled in an&nbsp;in vitro&nbsp;fertilization program.</li>
	<li>Primary ovarian failure should be excluded by the determination of gonadotropin levels.</li>
	<li>Appropriate evaluation should be performed to exclude pregnancy.</li>
	<li>Patients in later reproductive life have a greater predisposition to endometrial carcinoma as well as a higher incidence of anovulatory disorders. A thorough diagnostic evaluation should always be performed in patients who demonstrate abnormal&nbsp;uterine bleeding&nbsp;or other signs of endometrial abnormalities before starting FSH and Choriogonadotropin Alfa PreFilled Syringe therapy.</li>
	<li>Evaluation of the partner&#39;s fertility potential should be included in the initial evaluation.</li>
</ul>